Life sciences company Bio-Techne (NASDAQ:TECH) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 1.5% year on year to $311.4 million...
Life sciences company Bio-Techne (NASDAQ:TECH) fell short of the market’s revenue expectations in Q1 CY2026, with sales falling 1.5% year on year to $311.4 m...
Life sciences company Bio-Techne (NASDAQ:TECH) will be reporting results this Wednesday morning. Here’s what to look for. Bio-Techne beat analysts’ revenue e...
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
Bio-Techne trades at $56.99 and has moved in lockstep with the market. Its shares have returned 7.7% over the last six months while the S&P 500 has gained 5....
